8-K: PepGen Shifts Strategic Focus to DM1 Program After Disappointing Duchenne Muscular Dystrophy Trial Results

PepGen Inc. announced the discontinuation of its Duchenne muscular dystrophy (DMD) program, PGN-EDO51, following insufficient dystrophin protein levels in its CONNECT1-EDO51 study, and will now prioritize its promising myotonic dystrophy type 1 (DM1) program, PGN-EDODM1.

Summary

• PepGen Inc. is voluntarily discontinuing the development of PGN-EDO51 for Duchenne muscular dystrophy (DMD) and will wind down all DMD-related research and development activities.
• The decision was based on results from the 10 mg/kg cohort (n=4) of the CONNECT1-EDO51 study, where PGN-EDO51 increased exon 51 skipped transcripts to 4.26% (a mean increase of 3.5%), but total dystrophin only increased to 0.59% of normal levels (a mean increase of 0.36%).
• Despite the efficacy outcome, the safety profile of PGN-EDO51 was generally favorable, with all treatment-related adverse events being mild and no serious adverse events reported.
• The company will now focus its resources on advancing its myotonic dystrophy type 1 (DM1) program, PGN-EDODM1, which is currently in Phase 2 clinical development.
• PGN-EDODM1 has previously demonstrated robust target engagement, with a mean mis-splicing correction of 29% after a single 10 mg/kg dose in DM1 patients, along with a favorable emerging safety profile as of February 24, 2025.
• PepGen expects to report data from its FREEDOM-DM1 15 mg/kg cohort in the second half of 2025.
• Initial data from the FREEDOM2-DM1 5 mg/kg cohort is anticipated in the first quarter of 2026.
• The company's existing cash is expected to fund operations for 12 months based on the current operating plan as of May 8, 2025.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the outright failure and discontinuation of a significant clinical program (DMD). While the pivot to the DM1 program is presented positively with promising early data and upcoming milestones, the immediate impact of a failed trial outweighs the future potential, leading to a net negative sentiment. The company's cash runway is also limited to 12 months.

Positives

• The safety profile of PGN-EDO51 in the CONNECT1 study was generally favorable, with only mild treatment-related adverse events and no serious adverse events reported.
• The DM1 program (PGN-EDODM1) has shown promising early results, including a mean mis-splicing correction of 29% after a single 10 mg/kg dose and a favorable emerging safety profile.
• PGN-EDODM1 has received Orphan Drug and Fast Track Designations from the U.S. FDA for the treatment of DM1, indicating potential for expedited review.
• The company is strategically re-focusing its resources on the DM1 program, which addresses a significant unmet medical need with no approved treatments for the underlying cause.

Negatives

• PGN-EDO51 failed to achieve target dystrophin levels in the CONNECT1-EDO51 study, with total dystrophin increasing to only 0.59% of normal levels (a mean increase of 0.36%).
• The company is voluntarily discontinuing all Duchenne muscular dystrophy (DMD)-related research and development activities, including the PGN-EDO51 program.
• The discontinuation of the DMD program represents a significant setback for the company's pipeline and a loss of investment in that therapeutic area.

Risks

• Delays or failure to successfully initiate or complete ongoing and planned development activities for product candidates, including PGN-EDODM1.
• Challenges in enrolling patients in clinical trials, including FREEDOM and FREEDOM2.
• The company's interpretation of clinical and preclinical study results may be incorrect, or anticipated levels of therapeutic activity may not be observed in clinical testing for PGN-EDODM1.
• Product candidates, including PGN-EDODM1, may not be safe and effective or demonstrate safety and efficacy in clinical trials.
• Adverse outcomes from regulatory interactions, including delays in regulatory review, clearance to proceed, or approval by regulatory authorities.
• Changes in the regulatory framework that are beyond the company's control.
• Unexpected increases in expenses associated with development activities or other events that adversely impact financial resources and cash runway.
• Dependence on third parties for aspects of product manufacturing, research, and preclinical and clinical testing.

Future Outlook

PepGen will focus its resources on advancing the DM1 clinical program, PGN-EDODM1, with expected data readouts from the FREEDOM-DM1 15 mg/kg cohort in the second half of 2025 and initial data from the FREEDOM2-DM1 5 mg/kg cohort in the first quarter of 2026. The company aims to continue developing its research pipeline for severe neuromuscular and neurological diseases.

Management Comments

• James McArthur, PhD, President and CEO of PepGen, stated: "We are disappointed by the dystrophin results observed in the 10 mg/kg dose cohort in CONNECT1, as it was our hope that we could improve upon existing therapies for patients in a more profound way."
• McArthur also extended thanks to "the patients, families, caregivers, investigators and study staff for their support and participation in this research" and acknowledged "our teams hard work and commitment to advancing new potential treatments for DMD patients."
• Paul Streck, MD, MBA, Executive Vice President, Head of R&D of PepGen, commented: "PGN-EDODM1, PepGen's investigational drug in development for DM1, has already demonstrated robust target engagement after a single 10 mg/kg dose in patients that resulted in mean mis-splicing correction of 29% with a favorable emerging safety profile."
• Streck added: "Going forward, we will focus our resources on advancing the Company's ongoing DM1 clinical program along with our research pipeline."

Industry Context

PepGen operates in the biotechnology sector, specializing in oligonucleotide therapies for severe neuromuscular and neurological diseases. The discontinuation of a DMD program highlights the high-risk nature of drug development, particularly in rare genetic disorders. The pivot to Myotonic Dystrophy Type 1 (DM1) is significant as DM1 is a progressively disabling, life-shortening genetic disorder affecting an estimated 40,000 people in the United States and over 74,000 in Europe, with no currently approved treatments that address the underlying cause. This strategic shift positions PepGen to address a critical unmet medical need with its proprietary Enhanced Delivery Oligonucleotide (EDO) platform, which aims to improve the uptake and activity of conjugated oligonucleotide therapeutics.

Comparison to Industry Standards

• The document does not provide specific comparative data against other companies' DMD or DM1 programs, nor does it list specific comparable projects or their results.
• Management's statement about hoping to 'improve upon existing therapies for patients in a more profound way' for DMD implies a benchmark of current treatments, but no specific companies or drug names are mentioned for direct comparison.
• For DM1, the document highlights that 'currently patients have no approved treatment options for this disabling, life-shortening disorder,' indicating a significant unmet medical need rather than a competitive landscape with established standards.

Stakeholder Impact

• **Shareholders**: Likely negative impact due to the failure and discontinuation of a key clinical program, potentially leading to a decrease in share price. However, the strategic pivot to a promising DM1 program could mitigate long-term concerns if successful.
• **Patients (DMD)**: Disappointing news for Duchenne muscular dystrophy patients amenable to exon 51 skipping, as a potential new treatment option has been withdrawn.
• **Patients (DM1)**: Positive outlook for Myotonic Dystrophy Type 1 patients, as the company is now fully focusing resources on a promising candidate (PGN-EDODM1) for a disease with no approved treatments.
• **Employees**: Potential for restructuring or reallocation of resources as DMD-related R&D activities are wound down, impacting employees involved in those programs.
• **Creditors**: No direct impact mentioned, but the company's cash runway of 12 months suggests continued focus on financial management.

Next Steps

• Wind down all Duchenne muscular dystrophy (DMD)-related research and development activities.
• Continue advancing the myotonic dystrophy type 1 (DM1) program, PGN-EDODM1.
• Report data from the FREEDOM-DM1 15 mg/kg cohort in the second half of 2025.
• Report initial data from the FREEDOM2-DM1 5 mg/kg cohort in the first quarter of 2026.

Key Dates

Recommendation

Keywords

Myotonic Dystrophy Type 1, DM1, Duchenne Muscular Dystrophy, DMD, PGN-EDODM1, PGN-EDO51, Oligonucleotide Therapies, Clinical Trials, Biotechnology, Neuromuscular Diseases, Genetic Disorders, SEC Filing, Drug Development, Orphan Drug, Fast Track Designation